Fresenius Kabi and Bayer Schering Pharma sign HESylation agreement

Published: 10-Jun-2009
Sustainability Research & Development

German firms Fresenius Kabi and Bayer Schering Pharma have signed a licensing agreement regarding limited use of Fresenius" HESylation technology. The technology is based on hydroxyethyl starch (HES) and prolongs the active half-life of proteins.


German firms Fresenius Kabi and Bayer Schering Pharma have signed a licensing agreement regarding limited use of Fresenius" HESylation technology. The technology is based on hydroxyethyl starch (HES) and prolongs the active half-life of proteins.

Fresenius Kabi will provide the appropriate HES derivative to Bayer Schering Pharma and Bayer Schering will oversee the development and commercialisation. Fresenius Kabi will receive milestone payments and royalties on sales.

HESylation technology allows a targeted modification of drugs and their characteristics by a site-specific coupling to HES molecules. This can modify key pharmacological parameters such as absorption, metabolisation, half-life, water solubility and safety.

  • Companies:
  • Bayer
  • Fresenius-Kabi
See more

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Read more
Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  5. Five critical design elements for Pelton wheel turbine flowmeters Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Drug Delivery

Bayer and DelSiTech link up to develop new ophthalmology drug delivery technology

Agreement highlights the potential of biodegradable silica material in demanding drug delivery applications
Research & Development

Casebia Therapeutics establishes operations in Cambridge (MA, USA)

Hiring is underway and efforts have begun on haematology and ophthalmology programmes
Subscribe now